Available on demand. The demonstration of similar immunogenicity is a critical requirement for the demonstration of similarity between a biosimilar candidate and the respective reference product.
Find out more about the co-development agreement between Xbrane and STADA for a ranibizumab biosimilar, and about a novel biomarker test for establishing lung cancer risk in smokers in this week’s bioanalytical news round-up.
The first biosimilar for the treatment of breast and stomach cancers has been approved by the FDA, termed Ogivri.
Boehringer Ingelheim has announced that the interchangeability study for their adalimumab biosimilar candidate has begun.
Biotechnology company, BIOCAD (St. Petersburg, Russia), announced that its rituximab biosimilar has received recommendation for approval in India.
Biosimilar trastuzumab candidate (CT-P6) shown to be similar in efficacy and safety to the reference trastuzumab in data presented at the 2017 American Society of Clinical Oncology Annual Meeting (IN, USA).